|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-2-13
|
|
pubmed:abstractText |
Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1558-7673
|
|
pubmed:author |
pubmed-author:ChattaGurkamalG,
pubmed-author:CheungEricE,
pubmed-author:DorffTanyaT,
pubmed-author:GandaraDavid RDR,
pubmed-author:GroshenSusanS,
pubmed-author:LaraPrimo NPNJr,
pubmed-author:MaurerBarry JBJ,
pubmed-author:McNamaraMarkM,
pubmed-author:PinskiJacekJ,
pubmed-author:QuinnDavid IDI,
pubmed-author:ReynoldsC PatrickCP,
pubmed-author:Tsao-WeiDenice DDD,
pubmed-author:TwardowskiPrzemyslawP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
43-50
|
|
pubmed:meshHeading |
pubmed-meshheading:19213668-Adenocarcinoma,
pubmed-meshheading:19213668-Aged,
pubmed-meshheading:19213668-Aged, 80 and over,
pubmed-meshheading:19213668-Androgen Antagonists,
pubmed-meshheading:19213668-Antineoplastic Agents,
pubmed-meshheading:19213668-Disease Progression,
pubmed-meshheading:19213668-Fenretinide,
pubmed-meshheading:19213668-Humans,
pubmed-meshheading:19213668-Male,
pubmed-meshheading:19213668-Middle Aged,
pubmed-meshheading:19213668-Neoplasm Recurrence, Local,
pubmed-meshheading:19213668-Neoplasm Staging,
pubmed-meshheading:19213668-Prostatectomy,
pubmed-meshheading:19213668-Prostatic Neoplasms,
pubmed-meshheading:19213668-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
|
|
pubmed:affiliation |
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
